Amunix: Sanofi to buy cancer immunotherapy biotech for $1B
The French drugmaker is interested in Amunix Pharmaceuticals' technology, which could allow for more precise delivery of biologic drugs into cancerous tissue.
Read full article »
Amunix is a California-based biotechnology company that develops and markets T-cell and cytokine therapies for the treatment of cancer.
Read more